Compare FSFG & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSFG | TVGN |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 89.6M |
| IPO Year | 2008 | N/A |
| Metric | FSFG | TVGN |
|---|---|---|
| Price | $31.77 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $31.50 | $5.00 |
| AVG Volume (30 Days) | 18.4K | ★ 1.5M |
| Earning Date | 01-27-2026 | 11-14-2025 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.59 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $0.30 |
| 52 Week High | $33.35 | $1.92 |
| Indicator | FSFG | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 41.35 |
| Support Level | $32.06 | $0.30 |
| Resistance Level | $32.85 | $0.41 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 23.67 | 49.69 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.